
David Jiménez 🇪🇸
@djc6998
Senior consultant, Head of the Respiratory Department, Ramón y Cajal Hospital. CIBERES. Universidad de Alcalá
ID: 1677590900
17-08-2013 07:18:12
4,4K Tweet
1,1K Followers
981 Following



We summarized the guideline recs for #anticoagulant& #antiplatelettherapy in ACS & compared them w prior recs in American College of Cardiology AHA Science & European Society of Cardiology guidelines. 🙏🙏 Writing Committee and also a great team who made this summary possible 👇👇: jacc.org/doi/10.1016/j.…


Important info RE safety of #XI/XIa inhibitors in JACC Journals study of peri-procedural 🩸 Sid M. Patel TIMI Study Group jacc.org/doi/10.1016/j.… w a nice Editorial by experts: tinyurl.com/6uhawb4b In an Editor's note, I share hope & ? RE efficacy. 👇 tinyurl.com/ycycumcn


Potentially less #procedural #bleeding with long-acting #FXI inhibition than #DOACs: Simplified management paradigms pubmed.ncbi.nlm.nih.gov/40499984/ The PERT Consortium® Vasculearn Network Thrombosis Canada CanVECTOR Network Thrombosis UK C. Michael Gibson MD Anticoagulation Forum World Thrombosis Day European Thrombosis & Haemostasis Alliance (ETHA) European Society of Cardiology


Gracias a SeparRespira por invitarme a hablar sobre el tratamiento de la ETV en el paciente con cáncer de pulmón en el Congreso Nacional de la SEPAR de Bilbao. #ETV #cancer #bilbao SEPAR Circulación Pulmonar Hosp. Germans Trias



Con 9.2 de IF Archivos de Bronconeumología (FI 9,2 D1) se consolida con la sexta mejor revista del mundo de neumología SeparRespira Gracias a todos:autores, revisores, equipo de SEPAR, equipo editorial, asesores y todos los que han confiado que podíamos llegar donde hemos llegado. Toca seguir luchando


Archivos de Bronconeumología (FI 9,2 D1). Now the sixth best journal in the world with its new Impact Factor of 9.2. Thank you to everyone, from the reviewers to the committees. Now it’s time to keep working to continue improving SeparRespira David de la Rosa Carrillo




The weather’s not the only thing heating up…the July edition of What’s Hot in Clots is here! 🔥☀️💥 Behnood Bikdeli brings you the latest: 🩸COBRRA: Apixaban > rivaroxaban for bleeding risk in VTE 🔷SPECTACULAR: Imaging in PE 📖New ACS guidelines in JACC Journals 🧪PCC > plasma





